Docket #: S17-409
Compounds targeting phospholipid synthesis to treat cancer and metabolic disease
Disease indication:
Cancer: Renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), lymphoma and potentially other MYC-driven cancer
Drug format: Small molecule compounds, alone or in combination with other chemotherapeutic drugs
Drug class: First-in-class
Target: enzymes in phospholipid metabolic pathway
Research stage and Preliminary data:
The inventors demonstrated that various lipogenesis inhibitors suppress cancer proliferation in human and murine lymphoma lines.
Continued research: The inventors continue to develop SAR for leads.
Background: Previous studies have shown that lipid metabolism is frequently perturbed in cancers. Using desorption electrospray mass spectrometry (DESI-MSI), the inventors showed that phospholipid metabolism is altered.
Mode of action: Inhibiting phospholipid metabolism disrupts cancer metabolism, suppressing cancer proliferation. To date, the inventors have demonstrated results for lymphomas, HCC and RCC.
Advantages
- First-in-class approach with potential for treating a wide range of cancers
- This is a novel target in oncology
Related Links
Patents
- Published Application: WO2019165232
- Published Application: 20210002240
- Issued: 11,702,394 (USA)
Similar Technologies
-
Combination of differentiation therapy and metabolic intervention to treat neuroblastoma S18-498Combination of differentiation therapy and metabolic intervention to treat neuroblastoma
-
RASER – a synthetic system for targeting therapy to tumors with hyperactive signaling S17-233RASER – a synthetic system for targeting therapy to tumors with hyperactive signaling
-
Prodrugs of PKC modulators for improved formulation, therapeutic efficacy and tolerability S16-443Prodrugs of PKC modulators for improved formulation, therapeutic efficacy and tolerability